ESTRO 2025 - Abstract Book

S1942

Clinical - Urology

ESTRO 2025

Conclusion: A relevant focal tumor boost could be delivered in 20 fractions external beam radiotherapy. In spite of slightly higher organ at risk doses (within constraints), no differences were observed in toxicity and quality of life.

Keywords: Prostate, hypofractionation, boost

References: 1.

Kerkmeijer LGW et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial. Journal of Clinical Oncology. 2021;39(7):787 – 96. 2. Hoskin PJ et al. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. Radiotherapy and Oncology. 2021;154:214 – 9. 3. Oh J et al. An Updated Analysis of the Survival Endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys. 2023;115(5):1061 – 70. 4. Teunissen FR et al. The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC) [...]. World J Urol. 2022;40(9):2205 – 12